Ammonia Solution, Strong
drugOn this page
Also known as AmmoniaAmmonia gasAmmonia solutionstrongAmmonia wateraromaticAmmonia-solutionAmmonium causticumAmmonium hydroxideAmmonium waterAqua ammoniaAqueous ammoniaE-527INS NO.527INS-527Nitro-silR 717 (ammonia)Refrigerent r717Spirit of hartshornStrong ammonia solution
Summary
Ammonia Solution, Strong (CHEMBL1160819) is an approved small-molecule EC 3.5.1.4 (amidase) inhibitor.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Clinical trials: 10
- Chemistry: 17.031 Da · H3N
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1160819 |
| Name | Ammonia Solution, Strong |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 222 |
| ChEBI | CHEBI:16134 |
| Molecular formula | H3N |
| Molecular weight | 17.031 |
| InChIKey | QGZKDVFQNNGYKY-UHFFFAOYSA-N |
SMILES: N
IUPAC name: azane
ChEBI definition: An azane that consists of a single nitrogen atom covelently bonded to three hydrogen atoms.
Pharmacological roles (ChEBI): neurotoxin, EC 3.5.1.4 (amidase) inhibitor.
Other ChEBI roles (chemical / environmental): nucleophilic reagent, metabolite, refrigerant, mouse metabolite, NMR chemical shift reference compound.
Also known as: Ammonia, Ammonia gas, Ammonia solution, strong, Ammonia water, aromatic, Ammonia-solution, Ammonium causticum, Ammonium hydroxide, Ammonium water, Aqua ammonia, Aqueous ammonia
Parent form; salt/anhydrous children: CHEMBL1201189
Patent coverage: 3,051,373 distinct patent families (7,020,945 SureChEMBL compound mentions), from 117 matched compound structure(s). One matched structure accounts for 7,020,367 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE4 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00586131 | PHASE4 | COMPLETED | Arterial pH and Total Body Nitrogen Balances in APD |
| NCT05868798 | PHASE1 | COMPLETED | Can Ammonium Inhalants Maintain Performance in Sleep Deprived Soldiers? |
| NCT01370265 | Not specified | COMPLETED | Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress |
| NCT01579370 | Not specified | COMPLETED | Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs) |
| NCT02015195 | Not specified | COMPLETED | Effective Treatments for Jellyfish Stings |
| NCT03043690 | Not specified | COMPLETED | A Pooled Analysis of the Data From Two Studies of Ammonium Succinate for Menopausal Symptoms |
| NCT03170817 | Not specified | COMPLETED | Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT |
| NCT04343209 | Not specified | COMPLETED | Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP) |
| NCT04585672 | Not specified | UNKNOWN | Ammonia Metabolism Assessed by Ammonia Infusion |
| NCT04742660 | Not specified | COMPLETED | The Effect of Glycyrrhizin on the Occurrence of Postoperative Nausea and Vomiting |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.